SNMMI

The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.

The newly FDA-cleared Symbia Pro.specta SPECT/CT Scanner, which reportedly offers a variety of enhanced capabilities including low-dose CT up to 64 slices and intuitive workflow guides, was launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting.

In what may be the first study to examine clinical and polysomnographic aspects of obstructive sleep apnea (OSA) and coronary microvascular disease (CMD), researchers said the frequency of OSA may be a significant factor in the development of heart disease and related complications.

Recently approved PMSA-targeted radiotracer can pinpoint biochemical recurrent prostate cancer in men with unhelpful standard imaging.

Patients with mild cognitive impairment who take lipophilic statins have a more than doubled risk of progressing to dementia.

Tested so far in animal models, this tracer could further the development of treatments for this life-threatening disease for which there are currently no therapies.

New therapy uses light from decaying radiopharmaceuticals to attack cancer cells from inside the body.

Using an external tracking device can lead to super-resolution that can potentially improve neurological disorder detection.

Use enables direct imaging of disease process.

Using advanced artificial intelligence can give patients a personalized assessment of their risk for significant events, such as heart attack or death.

Images reveal older adults with above-average cognitive abilities have a resistance to tau and amyloid proteins.

Using 18F-DCPyL PSMA PET/CT can pinpoint more cancers in men who have biochemical failure with initial treatment.

Using PET/MRI 18F NaF offers new functional measure for assessing degeneration of knee joints.

18F-FDG PET/MRI can identify pain generator locations, leading to changes in pain management.

Cardiac imaging with PET and MRI shows excellent diagnostic accuracy compared with SPECT-MPI.

Imaging visualizes rheumatoid arthritis inflammation in preclinical study.

PET finds hypometabolism in healthy brains that may indicate pre-Alzheimer’s disease.

PET imaging aids researchers in search for anti-nicotine vaccine, but shows there is still a lot of work to do.

SPECT/MR debuted this week at the SNMMI annual meeting as a new preclinical hybrid molecular imaging system with promises of higher resolution and lower dose.